Zensar Technologies has announced that the merger of its US-based, 100% step-down subsidiary, Bridgeview Life Sciences LLC, with Zensar Technologies Inc., USA, is now effective as of August 1, 2026. Filings for this merger were completed on July 30, 2026. The company also noted that filings related to the merger of another subsidiary, M3BI LLC, with Zensar Technologies Inc. are currently in progress, indicating ongoing corporate restructuring in its US operations.
US Subsidiary Merger Update
Zensar Technologies Limited has provided an important update regarding the merger of its US-based wholly owned subsidiaries. Following the in-principle approval from its Board of Directors, the company confirmed that the merger of Bridgeview Life Sciences LLC with Zensar Technologies Inc., USA has been successfully completed.
Key Dates and Progress
All necessary filings with relevant local authorities and state agencies for the Bridgeview Life Sciences LLC merger were finalized on July 30, 2026. Consequently, the merger officially became effective from August 1, 2026. The company received intimation of this effectiveness on July 31, 2026, at 03:00 a.m. IST.
Ongoing Merger Activities
In parallel, Zensar Technologies is also progressing with the merger of its other US-based subsidiary, M3BI LLC, with Zensar Technologies Inc. The filings pertaining to this merger are currently in progress, indicating continued efforts to streamline the company’s operational structure in the United States.
Source: BSE
